[{"id":"80d5522f-7e62-4840-9814-99046b8adfc5","acronym":"DEKA-1","url":"https://clinicaltrials.gov/study/NCT05704985","created_at":"2023-01-30T15:59:33.980Z","updated_at":"2025-02-25T17:31:52.518Z","phase":"Phase 1","brief_title":"Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors","source_id_and_acronym":"NCT05704985 - DEKA-1","lead_sponsor":"DEKA Biosciences","biomarkers":" EGFR • IL2 • IL10","pipe":" | ","alterations":" EGFR expression","tags":["EGFR • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • carboplatin • paclitaxel • 5-fluorouracil • capecitabine • oxaliplatin • DK210 (EGFR)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/03/2023","start_date":" 04/03/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-01-23"}]